Connect with us

Intended for US Healthcare Professionals Only.Important Safety Information

Watch IXINITY® patients share their success stories

IXINITY helps people with hemophilia B live life on their own terms

Discover why people are switching. Hear what IXINITY patients are saying about bleed control, flexible factor IX dosing, switching factor, and maintaining an active lifestyle.

Bleed control

IXINITY resolved most bleeds with just 1 infusion.1*

Flexible dosing

24-hour half-life1 helps patients achieve peak factor IX levels when needed.

Switching to IXINITY

“I’m happy I talked with my doctor and decided to switch to IXINITY.”

Maintaining an active lifestyle

Flexible dosing for your patients’ active, everyday lives.

Medexus Pharma:
Making Connections That Matter

With programs like FACTOR IT FORWARD, Medexus works to ensure patients with factor IX deficiency get the coverage they need.

Support for women

Addressing hemophilia in women by helping female patients get the care they deserve.

A company that cares

For your patients who value a company that puts patients first.

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022.

+ MORE

- LESS

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE: IXINITY® [coagulation factor IX (recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children ≥12 years of age with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

CONTRAINDICATIONS: IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

WARNINGS AND PRECAUTIONS: Hypersensitivity reactions, including anaphylaxis, have occurred with IXINITY. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions.

Thromboembolism has occurred with IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis).

Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts.

The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information.

You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes
No